Davita-Nephron Dialysis is a medicare approved dialysis facility center in Long Beach, California and it has 21 dialysis stations. It is located in Los Angeles county at 5820 Downey Avenue, Long Beach, CA, 90805. You can reach out to the office of Davita-Nephron Dialysis at (562) 663-0788. This dialysis clinic is managed and/or owned by Davita. Davita-Nephron Dialysis has the following ownership type - Profit. It was first certified by medicare in August, 1996. The medicare id for this facility is 052788 and it accepts patients under medicare ESRD program.
| Name | Davita-Nephron Dialysis |
|---|---|
| Location | 5820 Downey Avenue, Long Beach, California |
| No. of Dialysis Stations | 21 |
| Medicare ID | 052788 |
| Managed By | Davita |
| Ownership Type | Profit |
| Late Shifts | No |
| 5820 Downey Avenue, Long Beach, California, 90805 | |
| (562) 663-0788 | |
News Archive
Astellas Pharma Inc., a global pharmaceutical company, will commence a tender offer to acquire all outstanding shares of common stock of OSI Pharmaceuticals for $52.00 per share in cash, or an aggregate of approximately $3.5 billion on a fully diluted basis.
In what they are calling a surprising finding in a large study of men who completed questionnaires and allowed scientists to review their medical records, Johns Hopkins researchers report that men with a history of asthma were less likely than those without it to develop lethal prostate cancer.
Johns Hopkins Medicine researchers are attending the annual Conference on Retroviruses and Opportunistic Infections, where they are sharing their latest findings in the ongoing battle against HIV/AIDS and related infectious diseases with other top basic, translational and clinical researchers from around the world.
"The regional meeting to scale up collaborative TB/HIV activities in Africa kicked off in Maputo last week with presentations scheduled for 14 African country representatives to share progress and challenges in confronting TB/HIV co-infection in the most highly impacted region of the world," the Center for Global Health Policy's "Science Speaks" blog reports.
Cardio3 BioSciences, a leading Belgian biotechnology company specialising in cell-based therapies for the treatment of cardiovascular diseases, announced today promising results in a pre-clinical study of its proprietary C-Cath(R) catheter which is under development to administer a range of bio-therapeutics to the heart. C-Cath is designed to take into account organ tissue structure and properties to maximize patients' safety, improve performance and increase user confidence during the injection procedure.
› Verified 7 days ago
| NPI Number | 1508116377 |
| Organization Name | Nephron Dialysis |
| Doing Business As | Total Renal Care Inc |
| Address | 5820 Downey Ave Lakewood, California, 90805 |
| Phone Number | (562) 663-0788 |
News Archive
Astellas Pharma Inc., a global pharmaceutical company, will commence a tender offer to acquire all outstanding shares of common stock of OSI Pharmaceuticals for $52.00 per share in cash, or an aggregate of approximately $3.5 billion on a fully diluted basis.
In what they are calling a surprising finding in a large study of men who completed questionnaires and allowed scientists to review their medical records, Johns Hopkins researchers report that men with a history of asthma were less likely than those without it to develop lethal prostate cancer.
Johns Hopkins Medicine researchers are attending the annual Conference on Retroviruses and Opportunistic Infections, where they are sharing their latest findings in the ongoing battle against HIV/AIDS and related infectious diseases with other top basic, translational and clinical researchers from around the world.
"The regional meeting to scale up collaborative TB/HIV activities in Africa kicked off in Maputo last week with presentations scheduled for 14 African country representatives to share progress and challenges in confronting TB/HIV co-infection in the most highly impacted region of the world," the Center for Global Health Policy's "Science Speaks" blog reports.
Cardio3 BioSciences, a leading Belgian biotechnology company specialising in cell-based therapies for the treatment of cardiovascular diseases, announced today promising results in a pre-clinical study of its proprietary C-Cath(R) catheter which is under development to administer a range of bio-therapeutics to the heart. C-Cath is designed to take into account organ tissue structure and properties to maximize patients' safety, improve performance and increase user confidence during the injection procedure.
› Verified 7 days ago
| NPI Number | 1649298530 |
| Doing Business As | Nephron Dialysis Center Of Lakewood Llc |
| Address | 5820 Downey Avenue Long Beach, California, 90805 |
| Phone Number | (562) 663-0788 |
News Archive
Astellas Pharma Inc., a global pharmaceutical company, will commence a tender offer to acquire all outstanding shares of common stock of OSI Pharmaceuticals for $52.00 per share in cash, or an aggregate of approximately $3.5 billion on a fully diluted basis.
In what they are calling a surprising finding in a large study of men who completed questionnaires and allowed scientists to review their medical records, Johns Hopkins researchers report that men with a history of asthma were less likely than those without it to develop lethal prostate cancer.
Johns Hopkins Medicine researchers are attending the annual Conference on Retroviruses and Opportunistic Infections, where they are sharing their latest findings in the ongoing battle against HIV/AIDS and related infectious diseases with other top basic, translational and clinical researchers from around the world.
"The regional meeting to scale up collaborative TB/HIV activities in Africa kicked off in Maputo last week with presentations scheduled for 14 African country representatives to share progress and challenges in confronting TB/HIV co-infection in the most highly impacted region of the world," the Center for Global Health Policy's "Science Speaks" blog reports.
Cardio3 BioSciences, a leading Belgian biotechnology company specialising in cell-based therapies for the treatment of cardiovascular diseases, announced today promising results in a pre-clinical study of its proprietary C-Cath(R) catheter which is under development to administer a range of bio-therapeutics to the heart. C-Cath is designed to take into account organ tissue structure and properties to maximize patients' safety, improve performance and increase user confidence during the injection procedure.
› Verified 7 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that nephrologists always communicated and cared for them. | 56% | 67% |
| Patients who reported that nephrologists usually communicated and cared for them. | 16% | 15% |
| Patients who reported that nephrologists sometimes or never communicated and cared for them. | 28% | 18% |
| Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 49% | 60% |
| Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 26% | 26% |
| Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 25% | 14% |
News Archive
Astellas Pharma Inc., a global pharmaceutical company, will commence a tender offer to acquire all outstanding shares of common stock of OSI Pharmaceuticals for $52.00 per share in cash, or an aggregate of approximately $3.5 billion on a fully diluted basis.
In what they are calling a surprising finding in a large study of men who completed questionnaires and allowed scientists to review their medical records, Johns Hopkins researchers report that men with a history of asthma were less likely than those without it to develop lethal prostate cancer.
Johns Hopkins Medicine researchers are attending the annual Conference on Retroviruses and Opportunistic Infections, where they are sharing their latest findings in the ongoing battle against HIV/AIDS and related infectious diseases with other top basic, translational and clinical researchers from around the world.
"The regional meeting to scale up collaborative TB/HIV activities in Africa kicked off in Maputo last week with presentations scheduled for 14 African country representatives to share progress and challenges in confronting TB/HIV co-infection in the most highly impacted region of the world," the Center for Global Health Policy's "Science Speaks" blog reports.
Cardio3 BioSciences, a leading Belgian biotechnology company specialising in cell-based therapies for the treatment of cardiovascular diseases, announced today promising results in a pre-clinical study of its proprietary C-Cath(R) catheter which is under development to administer a range of bio-therapeutics to the heart. C-Cath is designed to take into account organ tissue structure and properties to maximize patients' safety, improve performance and increase user confidence during the injection procedure.
› Verified 7 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 63% | 62% |
| Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 20% | 20% |
| Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 17% | 18% |
| Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 55% | 62% |
| Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 32% | 26% |
| Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 13% | 12% |
News Archive
Astellas Pharma Inc., a global pharmaceutical company, will commence a tender offer to acquire all outstanding shares of common stock of OSI Pharmaceuticals for $52.00 per share in cash, or an aggregate of approximately $3.5 billion on a fully diluted basis.
In what they are calling a surprising finding in a large study of men who completed questionnaires and allowed scientists to review their medical records, Johns Hopkins researchers report that men with a history of asthma were less likely than those without it to develop lethal prostate cancer.
Johns Hopkins Medicine researchers are attending the annual Conference on Retroviruses and Opportunistic Infections, where they are sharing their latest findings in the ongoing battle against HIV/AIDS and related infectious diseases with other top basic, translational and clinical researchers from around the world.
"The regional meeting to scale up collaborative TB/HIV activities in Africa kicked off in Maputo last week with presentations scheduled for 14 African country representatives to share progress and challenges in confronting TB/HIV co-infection in the most highly impacted region of the world," the Center for Global Health Policy's "Science Speaks" blog reports.
Cardio3 BioSciences, a leading Belgian biotechnology company specialising in cell-based therapies for the treatment of cardiovascular diseases, announced today promising results in a pre-clinical study of its proprietary C-Cath(R) catheter which is under development to administer a range of bio-therapeutics to the heart. C-Cath is designed to take into account organ tissue structure and properties to maximize patients' safety, improve performance and increase user confidence during the injection procedure.
› Verified 7 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 75% | 80% |
| Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 25% | 20% |
| Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 68% | 68% |
| Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 23% | 20% |
| Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 9% | 12% |
News Archive
Astellas Pharma Inc., a global pharmaceutical company, will commence a tender offer to acquire all outstanding shares of common stock of OSI Pharmaceuticals for $52.00 per share in cash, or an aggregate of approximately $3.5 billion on a fully diluted basis.
In what they are calling a surprising finding in a large study of men who completed questionnaires and allowed scientists to review their medical records, Johns Hopkins researchers report that men with a history of asthma were less likely than those without it to develop lethal prostate cancer.
Johns Hopkins Medicine researchers are attending the annual Conference on Retroviruses and Opportunistic Infections, where they are sharing their latest findings in the ongoing battle against HIV/AIDS and related infectious diseases with other top basic, translational and clinical researchers from around the world.
"The regional meeting to scale up collaborative TB/HIV activities in Africa kicked off in Maputo last week with presentations scheduled for 14 African country representatives to share progress and challenges in confronting TB/HIV co-infection in the most highly impacted region of the world," the Center for Global Health Policy's "Science Speaks" blog reports.
Cardio3 BioSciences, a leading Belgian biotechnology company specialising in cell-based therapies for the treatment of cardiovascular diseases, announced today promising results in a pre-clinical study of its proprietary C-Cath(R) catheter which is under development to administer a range of bio-therapeutics to the heart. C-Cath is designed to take into account organ tissue structure and properties to maximize patients' safety, improve performance and increase user confidence during the injection procedure.
› Verified 7 days ago
| Dialysis patients with Hemoglobin data | 41 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 10 |
News Archive
Astellas Pharma Inc., a global pharmaceutical company, will commence a tender offer to acquire all outstanding shares of common stock of OSI Pharmaceuticals for $52.00 per share in cash, or an aggregate of approximately $3.5 billion on a fully diluted basis.
In what they are calling a surprising finding in a large study of men who completed questionnaires and allowed scientists to review their medical records, Johns Hopkins researchers report that men with a history of asthma were less likely than those without it to develop lethal prostate cancer.
Johns Hopkins Medicine researchers are attending the annual Conference on Retroviruses and Opportunistic Infections, where they are sharing their latest findings in the ongoing battle against HIV/AIDS and related infectious diseases with other top basic, translational and clinical researchers from around the world.
"The regional meeting to scale up collaborative TB/HIV activities in Africa kicked off in Maputo last week with presentations scheduled for 14 African country representatives to share progress and challenges in confronting TB/HIV co-infection in the most highly impacted region of the world," the Center for Global Health Policy's "Science Speaks" blog reports.
Cardio3 BioSciences, a leading Belgian biotechnology company specialising in cell-based therapies for the treatment of cardiovascular diseases, announced today promising results in a pre-clinical study of its proprietary C-Cath(R) catheter which is under development to administer a range of bio-therapeutics to the heart. C-Cath is designed to take into account organ tissue structure and properties to maximize patients' safety, improve performance and increase user confidence during the injection procedure.
› Verified 7 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 102 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 1005 |
| Percentage of adult patients getting regular hemodialysis at the center | 97 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Astellas Pharma Inc., a global pharmaceutical company, will commence a tender offer to acquire all outstanding shares of common stock of OSI Pharmaceuticals for $52.00 per share in cash, or an aggregate of approximately $3.5 billion on a fully diluted basis.
In what they are calling a surprising finding in a large study of men who completed questionnaires and allowed scientists to review their medical records, Johns Hopkins researchers report that men with a history of asthma were less likely than those without it to develop lethal prostate cancer.
Johns Hopkins Medicine researchers are attending the annual Conference on Retroviruses and Opportunistic Infections, where they are sharing their latest findings in the ongoing battle against HIV/AIDS and related infectious diseases with other top basic, translational and clinical researchers from around the world.
"The regional meeting to scale up collaborative TB/HIV activities in Africa kicked off in Maputo last week with presentations scheduled for 14 African country representatives to share progress and challenges in confronting TB/HIV co-infection in the most highly impacted region of the world," the Center for Global Health Policy's "Science Speaks" blog reports.
Cardio3 BioSciences, a leading Belgian biotechnology company specialising in cell-based therapies for the treatment of cardiovascular diseases, announced today promising results in a pre-clinical study of its proprietary C-Cath(R) catheter which is under development to administer a range of bio-therapeutics to the heart. C-Cath is designed to take into account organ tissue structure and properties to maximize patients' safety, improve performance and increase user confidence during the injection procedure.
› Verified 7 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Davita-Nephron Dialysis with elevated calcium levels.
| Patients with hypercalcemia | 105 |
| Hypercalcemia patient months | 1043 |
| Patients with Serumphosphor | 106 |
| Patients with Serumphosphor less than 3.5 mg/dL | 10 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 26 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 37 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 17 |
| Patients with Serumphosphor greater than 7 mg/dL | 10 |
News Archive
Astellas Pharma Inc., a global pharmaceutical company, will commence a tender offer to acquire all outstanding shares of common stock of OSI Pharmaceuticals for $52.00 per share in cash, or an aggregate of approximately $3.5 billion on a fully diluted basis.
In what they are calling a surprising finding in a large study of men who completed questionnaires and allowed scientists to review their medical records, Johns Hopkins researchers report that men with a history of asthma were less likely than those without it to develop lethal prostate cancer.
Johns Hopkins Medicine researchers are attending the annual Conference on Retroviruses and Opportunistic Infections, where they are sharing their latest findings in the ongoing battle against HIV/AIDS and related infectious diseases with other top basic, translational and clinical researchers from around the world.
"The regional meeting to scale up collaborative TB/HIV activities in Africa kicked off in Maputo last week with presentations scheduled for 14 African country representatives to share progress and challenges in confronting TB/HIV co-infection in the most highly impacted region of the world," the Center for Global Health Policy's "Science Speaks" blog reports.
Cardio3 BioSciences, a leading Belgian biotechnology company specialising in cell-based therapies for the treatment of cardiovascular diseases, announced today promising results in a pre-clinical study of its proprietary C-Cath(R) catheter which is under development to administer a range of bio-therapeutics to the heart. C-Cath is designed to take into account organ tissue structure and properties to maximize patients' safety, improve performance and increase user confidence during the injection procedure.
› Verified 7 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 61 |
| Patient months included in arterial venous fistula and catheter summaries | 513 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 71 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 3 |
News Archive
Astellas Pharma Inc., a global pharmaceutical company, will commence a tender offer to acquire all outstanding shares of common stock of OSI Pharmaceuticals for $52.00 per share in cash, or an aggregate of approximately $3.5 billion on a fully diluted basis.
In what they are calling a surprising finding in a large study of men who completed questionnaires and allowed scientists to review their medical records, Johns Hopkins researchers report that men with a history of asthma were less likely than those without it to develop lethal prostate cancer.
Johns Hopkins Medicine researchers are attending the annual Conference on Retroviruses and Opportunistic Infections, where they are sharing their latest findings in the ongoing battle against HIV/AIDS and related infectious diseases with other top basic, translational and clinical researchers from around the world.
"The regional meeting to scale up collaborative TB/HIV activities in Africa kicked off in Maputo last week with presentations scheduled for 14 African country representatives to share progress and challenges in confronting TB/HIV co-infection in the most highly impacted region of the world," the Center for Global Health Policy's "Science Speaks" blog reports.
Cardio3 BioSciences, a leading Belgian biotechnology company specialising in cell-based therapies for the treatment of cardiovascular diseases, announced today promising results in a pre-clinical study of its proprietary C-Cath(R) catheter which is under development to administer a range of bio-therapeutics to the heart. C-Cath is designed to take into account organ tissue structure and properties to maximize patients' safety, improve performance and increase user confidence during the injection procedure.
› Verified 7 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 78 |
| Hospitalization Rate in facility | 171.8 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 297.2 |
| Hospitalization Rate: Lower Confidence Limit | 102.4 |
News Archive
Astellas Pharma Inc., a global pharmaceutical company, will commence a tender offer to acquire all outstanding shares of common stock of OSI Pharmaceuticals for $52.00 per share in cash, or an aggregate of approximately $3.5 billion on a fully diluted basis.
In what they are calling a surprising finding in a large study of men who completed questionnaires and allowed scientists to review their medical records, Johns Hopkins researchers report that men with a history of asthma were less likely than those without it to develop lethal prostate cancer.
Johns Hopkins Medicine researchers are attending the annual Conference on Retroviruses and Opportunistic Infections, where they are sharing their latest findings in the ongoing battle against HIV/AIDS and related infectious diseases with other top basic, translational and clinical researchers from around the world.
"The regional meeting to scale up collaborative TB/HIV activities in Africa kicked off in Maputo last week with presentations scheduled for 14 African country representatives to share progress and challenges in confronting TB/HIV co-infection in the most highly impacted region of the world," the Center for Global Health Policy's "Science Speaks" blog reports.
Cardio3 BioSciences, a leading Belgian biotechnology company specialising in cell-based therapies for the treatment of cardiovascular diseases, announced today promising results in a pre-clinical study of its proprietary C-Cath(R) catheter which is under development to administer a range of bio-therapeutics to the heart. C-Cath is designed to take into account organ tissue structure and properties to maximize patients' safety, improve performance and increase user confidence during the injection procedure.
› Verified 7 days ago
The rate of readmission show you whether patients who were being treated regularly at Davita-Nephron Dialysis were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 24.6 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 37.8 |
| Readmission Rate: Lower Confidence Limit | 14.4 |
News Archive
Astellas Pharma Inc., a global pharmaceutical company, will commence a tender offer to acquire all outstanding shares of common stock of OSI Pharmaceuticals for $52.00 per share in cash, or an aggregate of approximately $3.5 billion on a fully diluted basis.
In what they are calling a surprising finding in a large study of men who completed questionnaires and allowed scientists to review their medical records, Johns Hopkins researchers report that men with a history of asthma were less likely than those without it to develop lethal prostate cancer.
Johns Hopkins Medicine researchers are attending the annual Conference on Retroviruses and Opportunistic Infections, where they are sharing their latest findings in the ongoing battle against HIV/AIDS and related infectious diseases with other top basic, translational and clinical researchers from around the world.
"The regional meeting to scale up collaborative TB/HIV activities in Africa kicked off in Maputo last week with presentations scheduled for 14 African country representatives to share progress and challenges in confronting TB/HIV co-infection in the most highly impacted region of the world," the Center for Global Health Policy's "Science Speaks" blog reports.
Cardio3 BioSciences, a leading Belgian biotechnology company specialising in cell-based therapies for the treatment of cardiovascular diseases, announced today promising results in a pre-clinical study of its proprietary C-Cath(R) catheter which is under development to administer a range of bio-therapeutics to the heart. C-Cath is designed to take into account organ tissue structure and properties to maximize patients' safety, improve performance and increase user confidence during the injection procedure.
› Verified 7 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Davita-Nephron Dialysis get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | 1.39 (As Expected) |
| SIR: Upper Confidence Limit | 2.63 |
| SIR: Lower Confidence Limit | .64 |
News Archive
Astellas Pharma Inc., a global pharmaceutical company, will commence a tender offer to acquire all outstanding shares of common stock of OSI Pharmaceuticals for $52.00 per share in cash, or an aggregate of approximately $3.5 billion on a fully diluted basis.
In what they are calling a surprising finding in a large study of men who completed questionnaires and allowed scientists to review their medical records, Johns Hopkins researchers report that men with a history of asthma were less likely than those without it to develop lethal prostate cancer.
Johns Hopkins Medicine researchers are attending the annual Conference on Retroviruses and Opportunistic Infections, where they are sharing their latest findings in the ongoing battle against HIV/AIDS and related infectious diseases with other top basic, translational and clinical researchers from around the world.
"The regional meeting to scale up collaborative TB/HIV activities in Africa kicked off in Maputo last week with presentations scheduled for 14 African country representatives to share progress and challenges in confronting TB/HIV co-infection in the most highly impacted region of the world," the Center for Global Health Policy's "Science Speaks" blog reports.
Cardio3 BioSciences, a leading Belgian biotechnology company specialising in cell-based therapies for the treatment of cardiovascular diseases, announced today promising results in a pre-clinical study of its proprietary C-Cath(R) catheter which is under development to administer a range of bio-therapeutics to the heart. C-Cath is designed to take into account organ tissue structure and properties to maximize patients' safety, improve performance and increase user confidence during the injection procedure.
› Verified 7 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Davita-Nephron Dialysis's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 66 |
| Transfusion Rate in facility | 39.4 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 95.3 |
| Transfusion Rate: Lower Confidence Limit | 18.2 |
News Archive
Astellas Pharma Inc., a global pharmaceutical company, will commence a tender offer to acquire all outstanding shares of common stock of OSI Pharmaceuticals for $52.00 per share in cash, or an aggregate of approximately $3.5 billion on a fully diluted basis.
In what they are calling a surprising finding in a large study of men who completed questionnaires and allowed scientists to review their medical records, Johns Hopkins researchers report that men with a history of asthma were less likely than those without it to develop lethal prostate cancer.
Johns Hopkins Medicine researchers are attending the annual Conference on Retroviruses and Opportunistic Infections, where they are sharing their latest findings in the ongoing battle against HIV/AIDS and related infectious diseases with other top basic, translational and clinical researchers from around the world.
"The regional meeting to scale up collaborative TB/HIV activities in Africa kicked off in Maputo last week with presentations scheduled for 14 African country representatives to share progress and challenges in confronting TB/HIV co-infection in the most highly impacted region of the world," the Center for Global Health Policy's "Science Speaks" blog reports.
Cardio3 BioSciences, a leading Belgian biotechnology company specialising in cell-based therapies for the treatment of cardiovascular diseases, announced today promising results in a pre-clinical study of its proprietary C-Cath(R) catheter which is under development to administer a range of bio-therapeutics to the heart. C-Cath is designed to take into account organ tissue structure and properties to maximize patients' safety, improve performance and increase user confidence during the injection procedure.
› Verified 7 days ago
The rate of mortality show you whether patients who were being treated regularly at Davita-Nephron Dialysis lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 492 |
| Mortality Rate in facility | 16 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 21.1 |
| Mortality Rate: Lower Confidence Limit | 11.9 |
News Archive
Astellas Pharma Inc., a global pharmaceutical company, will commence a tender offer to acquire all outstanding shares of common stock of OSI Pharmaceuticals for $52.00 per share in cash, or an aggregate of approximately $3.5 billion on a fully diluted basis.
In what they are calling a surprising finding in a large study of men who completed questionnaires and allowed scientists to review their medical records, Johns Hopkins researchers report that men with a history of asthma were less likely than those without it to develop lethal prostate cancer.
Johns Hopkins Medicine researchers are attending the annual Conference on Retroviruses and Opportunistic Infections, where they are sharing their latest findings in the ongoing battle against HIV/AIDS and related infectious diseases with other top basic, translational and clinical researchers from around the world.
"The regional meeting to scale up collaborative TB/HIV activities in Africa kicked off in Maputo last week with presentations scheduled for 14 African country representatives to share progress and challenges in confronting TB/HIV co-infection in the most highly impacted region of the world," the Center for Global Health Policy's "Science Speaks" blog reports.
Cardio3 BioSciences, a leading Belgian biotechnology company specialising in cell-based therapies for the treatment of cardiovascular diseases, announced today promising results in a pre-clinical study of its proprietary C-Cath(R) catheter which is under development to administer a range of bio-therapeutics to the heart. C-Cath is designed to take into account organ tissue structure and properties to maximize patients' safety, improve performance and increase user confidence during the injection procedure.
› Verified 7 days ago
Davita-United Dialysis Center Location: 3111 Long Beach Blvd., Long Beach, California, 90807 Phone: (562) 426-5155 |
U.S. Renal Care West Coast Dialysis Location: 3780 Kilroy Airport Way, Suite 110, Long Beach, California, 90806 Phone: (562) 989-3010 |
Davita-Nephron Dialysis Location: 5820 Downey Avenue, Long Beach, California, 90805 Phone: (562) 663-0788 |
U.S. Renal Care Long Beach Dialysis Location: 1045 Atlantic Avenue, Suite 108, Long Beach, California, 90813 Phone: (562) 435-3637 |
News Archive
Astellas Pharma Inc., a global pharmaceutical company, will commence a tender offer to acquire all outstanding shares of common stock of OSI Pharmaceuticals for $52.00 per share in cash, or an aggregate of approximately $3.5 billion on a fully diluted basis.
In what they are calling a surprising finding in a large study of men who completed questionnaires and allowed scientists to review their medical records, Johns Hopkins researchers report that men with a history of asthma were less likely than those without it to develop lethal prostate cancer.
Johns Hopkins Medicine researchers are attending the annual Conference on Retroviruses and Opportunistic Infections, where they are sharing their latest findings in the ongoing battle against HIV/AIDS and related infectious diseases with other top basic, translational and clinical researchers from around the world.
"The regional meeting to scale up collaborative TB/HIV activities in Africa kicked off in Maputo last week with presentations scheduled for 14 African country representatives to share progress and challenges in confronting TB/HIV co-infection in the most highly impacted region of the world," the Center for Global Health Policy's "Science Speaks" blog reports.
Cardio3 BioSciences, a leading Belgian biotechnology company specialising in cell-based therapies for the treatment of cardiovascular diseases, announced today promising results in a pre-clinical study of its proprietary C-Cath(R) catheter which is under development to administer a range of bio-therapeutics to the heart. C-Cath is designed to take into account organ tissue structure and properties to maximize patients' safety, improve performance and increase user confidence during the injection procedure.
› Verified 7 days ago